AU2001268146A1 - Use of mutant herpes viruses and anticancer agents in the treatment of cancer - Google Patents
Use of mutant herpes viruses and anticancer agents in the treatment of cancerInfo
- Publication number
- AU2001268146A1 AU2001268146A1 AU2001268146A AU2001268146A AU2001268146A1 AU 2001268146 A1 AU2001268146 A1 AU 2001268146A1 AU 2001268146 A AU2001268146 A AU 2001268146A AU 2001268146 A AU2001268146 A AU 2001268146A AU 2001268146 A1 AU2001268146 A1 AU 2001268146A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- cells
- fudr
- cell
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 60
- 239000002246 antineoplastic agent Substances 0.000 title claims description 33
- 241001529453 unidentified herpesvirus Species 0.000 title claims description 26
- 201000011510 cancer Diseases 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title description 36
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 138
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 71
- 229960004857 mitomycin Drugs 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- -1 caroplatin Chemical compound 0.000 claims description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 15
- 206010017758 gastric cancer Diseases 0.000 claims description 15
- 201000011549 stomach cancer Diseases 0.000 claims description 15
- 108010022394 Threonine synthase Proteins 0.000 claims description 12
- 102000005497 Thymidylate Synthase Human genes 0.000 claims description 12
- 229940044683 chemotherapy drug Drugs 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 101150096316 5 gene Proteins 0.000 claims description 10
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 8
- 239000002168 alkylating agent Substances 0.000 claims description 8
- 230000000340 anti-metabolite Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 229940100197 antimetabolite Drugs 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 239000002256 antimetabolite Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 229960000961 floxuridine Drugs 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 206010027191 meningioma Diseases 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 208000007538 neurilemmoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010039667 schwannoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 201000004404 Neurofibroma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 4
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 4
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960002436 cladribine Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 229960000908 idarubicin Drugs 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 229960002247 lomustine Drugs 0.000 claims description 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 4
- 229960003171 plicamycin Drugs 0.000 claims description 4
- 229960000624 procarbazine Drugs 0.000 claims description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 229960001052 streptozocin Drugs 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960001196 thiotepa Drugs 0.000 claims description 4
- 229960003087 tioguanine Drugs 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 229940127327 Thymidylate Synthetase Inhibitors Drugs 0.000 claims description 3
- 208000013076 thyroid tumor Diseases 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 176
- 230000000694 effects Effects 0.000 description 65
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 40
- 230000003612 virological effect Effects 0.000 description 35
- 241000700605 Viruses Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000002648 combination therapy Methods 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 230000010076 replication Effects 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 241000700584 Simplexvirus Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 230000000996 additive effect Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 229960001330 hydroxycarbamide Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000005778 DNA damage Effects 0.000 description 6
- 231100000277 DNA damage Toxicity 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000000174 oncolytic effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101150027249 RL1 gene Proteins 0.000 description 3
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 3
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- FTDHDKPUHBLBTL-SHYZEUOFSA-K dCDP(3-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 FTDHDKPUHBLBTL-SHYZEUOFSA-K 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000337 synergistic cytotoxicity Toxicity 0.000 description 3
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 101100004352 Escherichia coli lacZ gene Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000768 catecholaminergic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- OPTASPLRGRRNAP-DOMIDYPGSA-N 6-amino-1h-pyrimidin-2-one Chemical compound NC1=CC=N[14C](=O)N1 OPTASPLRGRRNAP-DOMIDYPGSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- 108010091634 CDP reductase Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000006478 Cecal Neoplasms Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 241000271527 Crotalus adamanteus Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000011758 DNA endoreduplication Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700328 Herpes simplex virus (type 1 / strain F) Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000016997 Lithostathine Human genes 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 101150093191 RIR1 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 102000017303 Stromelysin-3 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 101150085955 US11 gene Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 description 1
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007253 cellular alteration Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000179 crotalid venom Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000276 dose-dependent cytotoxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011462 intraperitoneal chemotherapy Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Description
USE OF MUTANT HERPES VIRUSES AND ANTICANCER AGENTS IN THE TREATMENT OF CANCER
Field of the Invention This invention relates to methods of treating cancer.
Background of the Invention
G207 is a ribonucleotide reductase-negative herpes simplex virus (HSV) type 1, which was designed for brain tumor therapy and is currently under clinical evaluation as new treatment for malignant glioma (Markert et al., Gene Ther. 7:867-874, 2000; Mineta et al., Nature Med. 1:983-943, 1995). Recently, this HSV mutant was shown to also demonstrate high oncolytic potency against colorectal cancer cells (Kooby et al., FASEB J. 13:1325-1334, 1999). Recently, this virus has also been found to be effective in experimental treatments of many types of cancers, including breast cancer (Wu et al., Cancer Research 61(7):3009-3015, 2001), prostate cancer (Oyama et al., Japanese Journal of Cancer Research 91(12): 1339-1344, 2000), colorectal cancer (Delman et al., Human Gene Therapy 11(18):2465-2472, 2000), gastric cancer (Journal of Molecular Medicine 78(3):166-174, 2000), bladder cancer (Oyama et al., Human Gene Therapy 11(12):1683-1693, 2000), ovarian cancer (Coukos et al., Cancer Gene Therapy 7(2):275- 283, 2000), head and neck cancer (Carew et al., Human Gene Therapy 10(10): 1599- 1606, 1999), and pancreatic cancer (Lee et al., Journal of Gastrointestinal Surgery 3(2):127-131, 1999).
G207 typifies the strategy used in many candidate oncolytic viruses that specifically target tumor cells by deletion of viral ribonucleotide reductase (RR) and γ 34.5. First, viral RR is inactivated by inserting the Escherichia coli lacZ gene into the infected cell protein 6 (ICP6) locus that codes for the large subunit of RR. RR catalyzes the reduction of ribonucleotides to the corresponding deoxyribonucleotides, thereby providing sufficient precursors for the de novo synthesis of DNA. In mammalian cells, RR is highly expressed during S-phase and under DNA damage/repair conditions (Bjorklund et al., Biochemistry 29:2452-5458, 1990; Chabes et al., J. Biol. Chem.
275:17747-17753, 2000; Engstom et al., J. Biol. Chem. 260:9114-9116, 1985; Filatov et al., J. Biol. Chem. 270:25239-25243, 1995; Tanaka et al., Nature 404:42-49, 2000). Most herpes viruses encode their own RR, and their replication is, therefore, independent of the host cell cycle (Boehmer et al., Annu. Rev. Biochem. 66:347-384, 1997; Roizman et al., Fields Virology, 3rd ed. Lippincott-Raven, Philadelphia 1996; Roizman et al., Fields Virology, 3rd ed. Lippincott-Raven, Philadelphia, 1996). The • inactivation of ICP6 in G207 makes viral DNA replication completely dependent on the cellular enzyme and, consequently, replication of this mutant becomes largely dependent on host cell conditions. It is, therefore, reasonable to conceive that cell cycle alterations or DNA damage/repair conditions might modulate the replication of this herpes vector. The second mutation in G207 is the deletion of both γι34.5 loci. The γι34.5 gene codes a protein (ICP34.5) with at least two functions. One allows HSV to replicate and spread within central nervous system (Chou et al., Science 250:1262-1266, 1990; Whitley et al., J. Clin. Invest. 91:2837-2843, 1993). The second function confers HSV with the ability to escape from a host defense mechanism against viral infections by preventing the cellular shut-off of protein synthesis (Chou et al., Proc. Natl. Acad. Sci. U.S.A. 92:10516-10520, 1995; He et al, Proc. Nad. Acad. Sci. U.S.A. 94:843-848, 1997). This function can be substituted by the ICP34.5 homologous domain of the cellular growth arrest and DNA damage protein 34 (GADD34), which is a protein that is induced by DNA damage (He et al, Proc. Natl. Acad. Sci. U.S.A. 94:843-848, 1997).
Chemotherapy is an established modality in the treatment of malignancies. Fluorodeoxyuridine (FUdR) is a widely used chemotherapeutic drug to treat colorectal cancer. It is rapidly converted to the active metabolite 2'-deoxy-5-fluorouridine 5' monophosphate (FdUMP) by phosphorylation via thymidine kinase. FdUMP inhibits the enzyme thymidylate synthetase (TS) by forming a covalent complex with both sulf ydryl residue of TS and methylenetetrahydrofolate. Inhibition of TS causes a depletion of deoxythymidine 5' triphosphate (dTTP) with subsequent imbalance of intracellular deoxynucleotide triphosphate pools (Daneberg et al., Mol. Cell Biochem. 43:49-57, 1982; Jackson, J. Biol. Chem. 253:7440-7446, 1978; Yoshioka et al., J. Biol. Chem. 262:8235-8241, 1987). This inhibition induces cytotoxicity through several mechanisms. Nucleotide pool imbalances have been shown to induce a specific endonuclease with double-strand breakage activity in FM3A cells (Yoshioka et al., J. Biol. Chem. 262:8235-8241, 1987). Other studies have demonstrated that excessive
dUTP/dTTP ratios result in uracil misincorporation and misrepair leading to DNA strand breaks (Ayusawa et al., J. Biol. Chem. 258:12448-12454, 1983; Goulian et al., Adv. Exp. Med. Biol. 195:89-95, 1986; Ingraham et al., Biochemistry 25:3225-3230, 1986). The ability of FUdR to be incorporated into nascent DNA has been suggested as another mechanism of cytotoxic action (Danenberg et al., Biochem. Biophys. Res. Commun. 102:654-658, 1981). Furthermore, FUdR has profound effects on cell cycle and DNA replication by causing early S-phase blockade, loss of histone HI, and retarded DNA elongation (D'Anna et al., Biochemistry 24:5020-5026, 1985).
FUdR and other thymidylate synthase inhibitors are examples of chemotherapeutic agents that act by disrupting the balance of nucleotide production in cells. Additional agents have similar effects, including pyrimidine analogs, purine analogs, methotrexate, and 5-FU hydroxyurea. Another type of chemotherapeutic agent, the antimetabolites, acts by interferring with DNA synthesis. Alkylating agents, some anticancer antibiotics, and intercalating agents act by direct interaction with DNA, and can lead to, for example, disruption in DNA synthesis and/or transcription, and possibly lead to DNA breakage. Mitomycin C (MMC) is an antitumor antibiotic, has a wide clinical spectrum of antitumor activity, and is standard therapy for gastric cancer (Kelsen, Seminars in Oncology 23:379-389, 1996). MMC binds DNA by mono- or bifunctional alkylation, leading to DNA strand cross-linking and inhibition of DNA synthesis (Verweij et al., Anti-Cancer Drugs 1:5-13, 1990).
Summary of the Invention The invention provides methods of treating cancer in patients. These methods involve administration of (i) an attenuated herpes virus in which a γ34.5 gene (or genes) and/or a ribonucleotide reductase gene is inactivated, and (ii) a chemotherapeutic drug to patients. An example of an attenuated herpes virus that can be used in these methods is G207. The chemotherapeutic drug can be, e.g., an alkylating agent, such as busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, or thiotepa; an antineoplastic antibiotic, such as bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin (e.g., mitomycin C), mitoxantrone, pentostatin, or plicamycin; an antimetabolite, such as a thymidylate synthetase inhibitor (e.g.,
fluorodeoxyuridine), cladribine, cytarabine, floxuridine, fludarabine, flurouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, or thioguanine.
Cancers that can be treated using the methods of the invention include, for example, astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary adenoma, medulloblastoma, head and neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, Hodgkin's lymphoma, non-Hodgkins lymphoma, hepatoma, mesothelioma, epidermoid carcinoma, and cancers of the blood. The viruses used in the methods of the invention can also include a gene encoding a heterologous gene product, such as a vaccine antigen or an immunomodulatory protein.
The invention further includes the use of the viruses and anticancer compounds described herein in the treatment of cancer, and the use of these agents in the preparation of medicaments for treating cancer. For example, the invention includes the use of the viruses described herein in the preparation of a medicament for administration to a patient in conjunction with an anticancer compound as described herein, as well as the use of such an anticancer compound in the preparation of a medicament for administration to a patient in conjunction with a virus as described herein. The invention provides several advantages. For example, as is discussed further below, the therapeutic agents used in the invention, mutant Herpes viruses and anticancer agents, have synergistic activities in the treatment of cancer. As a result of this synergism, a dose-reduction for each agent can be accomplished over a wide range of drug-effect levels, without sacrificing therapeutic efficacy. Using lower amounts of the agents has several benefits, including minimization of toxicity to treated patients, as well as decreased costs. An additional advantage of the methods of the invention is that medical professionals are very familiar with the use of many of the anticancer agents that are used in the invention. For instance, the toxicities of many of the agents used in the invention are well recognized, and therapies exist to treat any associated side effects. In addition, mutant herpes viruses that can be used in the invention replicate in, and thus destroy, dividing cells, such as cancer cells, while not affecting other, quiescent cells in the body. These herpes viruses can also be multiply mutated, thus eliminating the possibility of reversion to wild type. Moreover, if necessary, the replication of herpes
viruses can be controlled through the action of antiviral drugs, such as acyclovir, which block viral replication, thus providing another important safeguard. Finally, in some examples of the methods of the invention, anticancer agents, such as mitomycin C, are used to counteract the decreased replication phenotype γ34.5 gene deletions of certain herpes virus vectors, without the potential risk of increasing neurovirulence.
Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the claims.
Brief Description of the Drawings Figure 1 depicts the results of experiments showing the cytotoxic effects of
G207 and FUdR. Cell viability was assessed as function of maximal release of intracellular LDH. Upper figure panel, cytotoxicity of G207 and FUdR. HCT8 (black circle) and HCT8/7dR (white circle) were exposed to cumulative FUdR concentrations (5, 10, 50, 100 nM) and viability was determined at day 6 following start of treatment (A). Viral cytotoxicity in HCT8 (B) and HCT8/7dR (C) at day 3 and 6 pi. Cells were infected with G207 at an MOI of 1.0 (Δ), 0.1 (D), and 0.01 (O). Lower figure panel, cell viability for single (G207 or FUdR) and combined treatment in HCT8 (D) and HCT8/7dR (E) at day 6. Cells were infected with G207 at an MOI of 0.01 (white bar), exposed to FUdR (gray bar), or treated with G207 (MOI = 0.01) and FUdR (10 nM or 100 nM) in combination (black bar). Additive effects were calculated as product from each single treatment (oblique bar). All assays were performed in quadruplicate for each condition (avg ± SEM).
Figure 2 depicts the results of experiments showing the influence of FUdR on β- galactosidase expression following infection with G207. Cells (2 x 104) were plated in 24-well plates, and were infected with G207 at an MOI of 0.01 in presence (10 nM, oblique; 100 nM, black) and absence (white) of FUdR. At day 3 following infection, cells were lysed and total -galactosidase activity of cell lysates was measured (A). Cell counts for each condition were determined in additional wells by trypan blue exclusion and specific activity was calculated by referring total activity to viable cell number (B). All assays were performed in triplicates (avg ± SEM). For lacZ staining 3 x 105 cells were plated onto 25 cm2 flasks. Twelve hours later cells were infected with G207 in the presence and absence of FUdR under the same conditions as described above. At day 3 pi, cytospin slides were prepared and stained with X-gal for lacZ expression. Figure 2,
panel C shows representative fields at 200-fold magnification for different treatment conditions.
Figure 3 depicts the results of experiments showing the effect of FUdR on viral replication. Viral titers were determined to evaluate the influence of FUdR on viral replication. 5 x 104 cells were plated per well in 12-well plates. Twelve hours later, cells were infected at an MOI of 0.01 in presence (Δ 10 nM; O 100 nM) and absence (□ control) of FUdR. Supernatants and cells were harvested daily for following 7 days pi and lysates were titrated on Vero cells by standard plaque assay. All assays were performed in triplicates for each condition (avg ± SEM). Figure 4 depicts the results of experiments showing the effects of FUdR and HU on viral replication. HCT8 cells were infected with 2 pfu of G207 per cell. After adsorption of 1 hour at 37 °C inoculum was removed, cells were washed with PBS, and medium containing 10 nM FUdR or control medium without FUdR was added. At 8 hours pi, infected cells in presence and absence of FUdR were exposed to 1 mM HU. At 36 hours pi cells and supernatant were harvested and lysates were prepared by three cycles of freezing and thawing. Viral titers (A) and jS-galactosidase activity (B) of the lysate were determined. All assays were performed in triplicates for each condition (avg ± SEM).
Figure 5 depicts the results of experiments showing the effect of FUdR on the cell cycle. Asynchronously growing cells (1 x 106) were plated onto 75 cm2 in 20 ml of media. Twelve hours later FUdR was added to media to a final concentration of 10 nM and 100 nM. Untreated cells served as control. DNA content was measured on ethidium bromide-stained nuclei by FACS analysis at 24 h, 48 h, and 72 h following start of treatment. Cell cycle analysis of HCT8 (A) and HCT8/7dR (B) was performed based on the shown side scatter histograms. Histograms were gated for subGi fraction (DNA < Gi/Go) and DNA > G2/M.
Figure 6 depicts the results of experiments showing the effect of FUdR on cellular ribonucleotide reductase activity. 1 x 107 cells were plated onto 225 cm2 flasks. After 9 hours FUdR was added to the media to a final concentration of 10 nM and 100 nM. Untreated cells served as control. Ribonucleotide reductase activity was measured in cellular extracts at various time points in presence (Δ 10 nM; O 100 nM) and absence (D control) of FUdR. Activities were referred to cell count. All assays were performed in triplicate for each time point and condition (avg ± SEM).
Figure 7 depicts the results of experiments showing GADD34 expression in response to FUdR. Northern blots of GADD34 mRNA in HCT8 (A) and HCT8/7dR (B) cells grown in absence and presence of 10 nM and 100 nM FUdR for 24 and 48 hours. Cells were plated and treated with FUdR according to the experiment of RR measurement (see legend to Figure 5). β-actin served as loading controls for GADD34. Figure 8 depicts the results of experiments showing that combination chemotherapy and oncolytic viral therapy to kill gastric cancer cells demonstrates enhanced efficacy as compared to single agent therapy alone. OCUM-2MD3 (A) MKN- 45-P (B) gastric cancer cells were treated with different doses of Mitomycin C (μg/cc) or G207 (MOI). Combination therapy was performed to keep the ratio of MMC:G207 constant at 1:10 for the OCUM-2MD3 cells, and 1:25 for the MKN-45-P cells. Standard MTT assay was used to assess cytotoxicity for each treatment group with results presented as % survival as compared to control.
Figure 9 depicts the results of experiments showing that combination therapy using Mitomycin C and G207 demonstrates a synergistic interaction over the entire range of doses evaluated. The Chou-Talaley combination index method of evaluating synergy was performed as described in Methods (see below). The CI-Fa plot was constructed using experimental data points (dark circles) and by determining CI values over the entire range of Fa values from 5-95% (solid line) using CalcuSyn software. The additive effect of G207 and MMC is represented at CI=1 (dotted line). G207 and MMC combination therapy results in moderate synergy for the OCUM-2MD3 cell line (A) and strong synergy for the MKN-45-P cell line (B) at all effect levels.
Figure 10 depicts isobolograms that demonstrate synergism and dose-reduction with G207 and MMC combination therapy in both the OCUM-2MD3 cell line (A) and the MKN-45-P (B) cell line. The doses of MMC and G207 necessary to achieve 90% cell kill (open triangles), 70% cell kill (open squares) and 50% cell kill (open circles) are plotted on the axes, and the connecting solid lines represent the expected additive effects for combination therapy. Experimental combination therapy doses necessary to generate Fa values of 90% (dotted triangles), 70% (dotted squares) and 50% (dotted circles) all lie to the lower left of the corresponding lines, indicating synergism. A dose-reduction using combination therapy is also apparent at all three Fa values for both cell lines.
Figure 11 depicts the results of experiments showing the levels of GADD34 mRNA in OCUM cells exposed to MMC. mRΝA extracted from untreated OCUM cells served as the negative control for GADD34 (lane 1), while the positive control (lane 6) demonstrates a strong band at 2.4 kb, the size for GADD34 mRΝA. OCUM cells were treated for 24 and 48 hours with either low (0.005 μg/ml) or high dose MMC (0.04 μg/ml). At 24 h, low dose therapy did not result in upregulation of GADD34 mRΝA (lane 2), while high dose therapy resulted in a 2.49-fold increase in mRΝA as compared to the negative control (lane 3). At 48 h, low dose therapy failed to demonstrate the presence of GADD34 mRΝA (lane 4), while high dose therapy resulted in a 3.21-fold increase in mRΝA (lane 5).
Figure 12 depicts the results of experiments showing that intraperitoneal chemotherapy and viral therapy demonstrate enhanced tumor kill when given in combination for gastric carcinomatosis. Tumor burden was generated by i.p. injection of OCUM-2MD3 cells into athymic mice and treatment was initiated 3d later. Mice were injected i.p. with media (controls), lxlO6 pfu of G207, 0.1 μg kg MMC, or both agents given in combination. Tumor burden was assessed by weight at 4 weeks post-tumor cell inoculation. There was a significant reduction in tumor burden when comparing G207 therapy to controls (P=0.02), while MMC therapy only demonstrated a trend in tumor burden reduction (vs. controls) at this dose (P=0.06). Combination therapy resulted in the highest reduction in tumor burden when compared to controls (P<0.001), and also showed a significant reduction when compared to G207 therapy (P=0.03) or MMC therapy (P=0.01) alone. Statistical analysis was performed using a two-tailed, Students t-test.
Detailed Description
The invention provides methods of treating cancer that involve administration of mutant herpes viruses in conjunction with anticancer agents. As is discussed further below, such a combined approach can lead to synergistic effects in the treatment of cancer, thus providing substantial therapeutic benefits (e.g., administration of decreased amounts of potentially toxic chemotherapeutic agents, without loss of therapeutic effect). Examples of mutant herpes viruses and anticancer agents. that can be used in the invention, as well as modes of their administration, are provided below. Also provided
below are examples of cancers that can be treated using the methods of the invention, as well as experimental results showing the efficacy of these methods.
Mutant Herpes Viruses Mutant viruses that can be used in the invention can be derived from members of the family Herpesviridae (e.g., HSV-1, HSV-2, VZV, CMV, EBV, HHV-6, HHV-7, and HHV-8). Specific examples of attenuated HSV mutants that can be used in the invention include G207 (Yazaki et al., Cancer Res. 55(21):4752-4756, 1995), HF (ATCC VR-260), Maclntyre (ATCC VR-539), MP (ATCC VR-735); HSV-2 strains G (ATCC VR-724) and MS (ATCC VR-540), as well as mutants having mutations in one or more of the following genes: the immediate early genes ICPO, ICP22, and ICP47 (U.S. Patent No. 5,658,724); the γ34.5 gene; the ribonucleotide reductase gene; and the VP16 gene (i.e., Vmw65, WO 91/02788; WO 96/04395; WO 96/04394). The vectors described in U.S. Patent Nos. 6,106,826 and 6,139,834 can also be used. As is discussed further below, a preferred mutant herpes virus for use in the methods of the invention has an inactivating mutation, deletion, or insertion in one or both γ34.5 genes and/or a ribonucleotide reductase gene. One example of such a mutant herpes virus is G207, which, as is described above, has deletions in both copies of the γ34.5 gene, which encodes the major determinant of HSV neurovirulence. G207 also includes an inactivating insertion in UL39, which is the gene encoding infected-cell protein 6 (ICP6), the large subunit of ribonucleotide reductase of this virus.
An additional examples of a Herpes virus mutant that can be used in the invention is G47Δ, which is a multimutated, replication-competent HSV-1 vector, derived from G207 by a 312 basepair deletion within the non-essential a47 gene (Mavromara-Nazos et al, J. Virol. 60:807-812, 1986). Because of the overlapping transcripts encoding ICP47 and US 11 in HSV, the deletion in a47 also places the late US11 gene under control of the immediate-early a47 promoter, which enhances the growth properties of γ34.5~ mutants. An HSV-1 mutant designated hrR3, which is ribonucleotide reductace-defective, can also be used in the invention (Spear et al., Cancer Gene Ther. 7(7): 1051-1059, 2000).
The effects of the viruses used in the methods of the invention can be augmented if the virus also contains a heterologous nucleic acid sequence encoding one or more therapeutic products, for example, a cytotoxin, an immunomodulatory protein (i.e., a
protein that either enhances or suppresses a host immune response to an antigen), a tumor antigen, an antisense RNA molecule, or a ribozyme. Examples of immunomodulatory proteins include, e.g., cytokines (e.g., interleukins, for example, any of interleukins 1-15, α, β, or γ-interferons, tumor necrosis factor, granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and granulocyte colony stimulating factor (G-CSF)), chemokines (e.g., neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, and macrophage inflammatory peptides MlP-la and MlP-lb), complement components and their receptors, immune system accessory molecules (e.g., B7.1 and B7.2), adhesion molecules (e.g., ICAM-1, 2, and 3), and adhesion receptor molecules. Examples of tumor antigens that can be produced as a result of using the present methods include, e.g., the E6 and E7 antigens of human papillomavirus, EBV- derived proteins (Van der Bruggen et al., Science 254:1643-1647, 1991), mucins (Livingston et al., Cur. Opin. Immun. 4(5):624-629, 1992), such as MUC1 (Burchell et al., Int. J. Cancer 44:691-696, 1989), melanoma tyrosinase, and MZ2-E (Van der
Bruggen et al, supra). (Also see WO 94/16716 for a further description of modification of viral vectors to include genes encoding tumor antigens or cytokines.)
As is noted above, the heterologous therapeutic product can also be an RNA molecule, such as an antisense RNA molecule that, by hybridization interactions, can be used to block expression of a cellular or pathogen mRNA. Alternatively, the RNA molecule can be a ribozyme (e.g., a hammerhead or a hairpin-based ribozyme) designed either to repair a defective cellular RNA, or to destroy an undesired cellular or pathogen- encoded RNA (see, e.g., SuUenger, Chem. Biol. 2(5):249-253, 1995; Czubayko et al., Gene Ther. 4(9). -943-949, 1997; Rossi, Ciba Found. Symp. 209:195-204, 1997; James et al., Blood 91(2):371-382, 1998; SuUenger, Cytokines Mol. Ther. 2(3):201-205, 1996; Hampel, Prog. Nucleic Acid Res. Mol. Bio. 58:1-39, 1998; Curcio et al., Pharmacol. Ther. 74(3):317-332, 1997).
A heterologous nucleic acid sequence can be inserted into a virus for use in the methods of the invention in a location that renders it under the control of a regulatory sequence of the virus. Alternatively, the heterologous nucleic acid sequence can be inserted as part of an expression cassette that includes regulatory elements, such as promoters or enhancers. Appropriate regulatory elements can be selected by one of ordinary skill in the art based on, for example, the desired tissue-specificity and level of
expression. For example, a cell-type specific or tumor-specific promoter can be used to limit expression of a gene product to a specific cell type. This is particularly useful, for example, when a cytotoxic, immunomodulatory, or tumor antigenic gene product is being produced in a tumor cell in order to facilitate its destruction. In addition to using tissue-specific promoters, local administration of the viruss of the invention can result in localized expression and effect.
Examples of non-tissue specific promoters that can be used in the invention include the early Cytomegalovirus (CMV) promoter (U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (Norton et al., Molec. Cell Biol. 5:281, 1985). Also, HSV promoters, such as HSV-1 IE and IE 4/5 promoters, can be used.
Examples of tissue-specific promoters that can be used in the invention include, for example, the prostate-specific antigen (PSA) promoter, which is specific for cells of the prostate; the desrnin promoter, which is specific for muscle cells (Li et al., Gene 78:243, 1989; Li et al., J. Biol. Chem. 266:6562, 1991; Li et al., J. Biol. Chem. 268:10403, 1993); the enolase promoter, which is specific for neurons (Forss-Petter et al., J. Neuroscience Res. 16(1):141-156, 1986); the β-globin promoter, which is specific for erythroid cells (Townes et al., EMBO J. 4:1715,1985); the tau-globin promoter, which is also specific for erythroid cells (Brinster et al., Nature 283:499, 1980); the growth hormone promoter, which is specific for pituitary cells (Behringer et al., Genes Dev. 2:453, 1988); the insulin promoter, which is specific for pancreatic β cells (Selden et al., Nature 321:545, 1986); the glial fibrillary acidic protein promoter, which is specific for astrocytes (Brenner et al., J. Neurosci. 14:1030, 1994); the tyrosine hydroxylase promoter, which is specific for catecholaminergic neurons (Earn et al., J. Biol. Chem. 268:15689, 1993); the amyloid precursor protein promoter, which is specific for neurons (Salbaum et al., EMBO J. 7:2807, 1988); the dopamine β- hydroxylase promoter, which is specific for noradrenergic and adrenergic neurons (Hoyle et al., J. Neurosci. 14:2455, 1994); the tryptophan hydroxylase promoter, which is specific for serotonin/pineal gland cells (Boularand et al., J. Biol. Chem. 270:3757, 1995); the choline acetyltransferase promoter, which is specific for cholinergic neurons (Hersh et al., J. Neurochem. 61 :306, 1993); the aromatic L-amino acid decarboxylase (AADC) promoter, which is specific for catecholaminergic/5-HT/D-type cells (Thai et al., Mol. Brain Res. 17:227, 1993); the proenkephalin promoter, which is specific for neuronal/spermatogenic epididymal cells (Borsook et al., Mol. Endocrinol. 6:1502,
1992); the reg (pancreatic stone protein) promoter, which is specific for colon and rectal tumors, and pancreas and kidney cells (Watanabe et al., J. Biol. Chem. 265:7432, 1990); and the parathyroid hormone-related peptide (PTHrP) promoter, which is specific for liver and cecum tumors, and neurilemoma, kidney, pancreas, and adrenal cells (Campos et al., Mol. Rnfovtinol. 6: 1642, 1992).
Examples of promoters that function specifically in tumor cells include the stromelysin 3 promoter, which is specific for breast cancer cells (Basset et al, Nature 348:699, 1990); the surfactant protein A promoter, which is specific for non-small cell lung cancer cells (Smith et al., Hum. Gene Ther. 5:29-35, 1994); the secretory leukoprotease inhibitor (SLPI) promoter, which is specific for SLPI-expressing carcinomas (Garver et al., Gene Ther. 1:46-50, 1994); the tyrosinase promoter, which is specific for melanoma cells (Vile et al, Gene Therapy 1:307, 1994; WO 94/16557; WO 93/GB1730); the stress inducible grp78/BiP promoter, which is specific for fibrosarcoma/tumorigenic cells (Gazit et al., Cancer Res. 55(8): 1660, 1995); the AP2 adipose enhancer, which is specific for adipocytes (Graves, J. Cell. Biochem. 49:219, 1992); the α-1 antitrypsin transthyretin promoter, which is specific for hepatocytes (Grayson et al., Science 239:786, 1988); the interleukin-10 promoter, which is specific for glioblastoma multiform cells (Nitta et al., Brain Res. 649:122, 1994); the c-erbB-2 promoter, which is specific for pancreatic, breast, gastric, ovarian, and non-small cell lung cells (Harris et al., Gene Ther. 1:170, 1994); the α-B-crystallin/heat shock protein 27 promoter, which is specific for brain tumor cells (Aoyama et al., Int. J. Cancer 55:760, 1993); the basic fibroblast growth factor promoter, which is specific for glioma and meningioma cells (Shibata et al., Growth Fact. 4:277, 1991); the epidermal growth factor receptor promoter, which is specific for squamous cell carcinoma, glioma, and breast tumor cells (Ishii et al., Proc. Natl. Acad. Sci. U.S.A. 90:282, 1993); the mucin- like glycoprotein (DF3, MUCl) promoter, which is specific for breast carcinoma cells (Abe et al., Proc. Natl. Acad. Sci. U.S.A. 90:282, 1993); the mtsl promoter, which is specific for metastatic tumors (Tulchinsky et al., Proc. Natl. Acad. Sci. U.S.A. 89:9146, 1992); the NSE promoter, which is specific for small-cell lung cancer cells (Forss-Petter et al., Neuron 5:187, 1990); the somatostatin receptor promoter, which is specific for small cell lung cancer cells (Bombardieri et al., Eur. J. Cancer 31A:184, 1995; Koh et al., Int. J. Cancer 60:843, 1995); the c-erbB-3 and c-erbB-2 promoters, which are specific for breast cancer cells (Quin et al., Histopathology 25:247, 1994); the c-erbB4
promoter, which is specific for breast and gastric cancer cells (Rajkumar et al., Breast Cancer Res. Trends 29:3, 1994); the thyroglobulin promoter, which is specific for thyroid carcinoma cells (Mariotti et al., J. Clin. Endocrinol. Meth. 80:468, 1995); the α- fetoprotein promoter, which is specific for hepatoma cells (Zuibel et al., J. Cell. Phys. 162:36, 1995); the villin promoter, which is specific for gastric cancer cells (Osborn et al., Virchows Arch. A. Pathol. Anat. Histopathol. 413:303, 1988); and the albumin promoter, which is specific for hepatoma cells (Huber, Proc. Natl. Acad. Sci. U.S.A. 88:8099, 1991).
The viruses can be administered by any conventional route used in medicine, either at the same time as an anticancer agent, as is described below, or shortly before or after anticancer agent administration. Also, the viruses can be administered by the same or a different route as the anticancer agent, as can be determined to be appropriate by those of skill in this art.
The viruses (or anticancer agents) used in the methods of the invention can be administered directly into a tissue in which an effect, e.g., cell killing and/or therapeutic gene expression, is desired, for example, by direct injection or by surgical methods (e.g., stereotactic injection into a brain tumor; Pellegrino et al., Methods in Psychobiology (Academic Press, New York, New York, 67-90, 1971)). An additional method that can be used to administer viruses into the brain is the convection method described by Bobo et al. (Proc. Natl. Acad. Sci. U.S.A. 91:2076-2080, 1994) and Morrison et al. (Am. J. Physiol. 266:292-305, 1994). In the case of tumor treatment, as an alternative to direct tumor injection, surgery can be carried out to remove the tumor, and the viruses inoculated into the resected tumor bed to ensure destruction of any remaining tumor cells. Alternatively, the viruses can be administered via a parenteral route, e.g., by an intravenous, intraarterial, intracerebroventricular, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route, or via a mucosal surface, e.g., an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, or urinary tract surface.
Any of a number of well-known formulations for introducing viral vectors into cells in mammals, such as humans, can be used in the invention. (See, e.g., Remington's Pharmaceutical Sciences (18th edition), ed. A. Gennaro, 1990, Mack Publishing Co.,
Easton, PA.) However, the viruses can be simply diluted in a physiologically acceptable solution, such as sterile saline or sterile buffered saline, with or without an adjuvant or carrier.
The amount of vector to be administered depends, e.g., on the specific goal to be achieved, the strength of any promoter used in the vector, the condition of the mammal (e.g., human) intended for administration (e.g., the weight, age, and general health of the mammal), the mode of administration, and the type of formulation. In general, a therapeutically or prophylactically effective dose of, e.g., from about 101 to 1010 plaque forming units (pfu), for example, from about 5xl04 to lxl06pfu, e.g., from about 1x10s to about 4xl05 pfu, although the most effective ranges may vary from host to host, as can readily be determined by one of skill in this art. Also, the administration can be achieved in a single dose or repeated at intervals, as determined to be appropriate by those of skill in this art.
Anticancer Agents
Any of numerous anticancer agents (i.e., chemotherapeutic agents) can be used in the methods of the invention. These compounds fall into several different categories, including, for example, alkylating agents, antineoplastic antibiotics, antimetabolites, and natural source derivatives. Examples of alkylating agents that can be used in the invention include busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide (i.e., cytoxan), dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, and thiotepa; examples of antineoplastic antibiotics include bleomycin, dactinomycin, daunorabicin, doxorubicin, idarubicin, mitomycin (e.g., mitomycin C), mitoxantrone, pentostatin, and plicamycin; examples of antimetabolites include fluorodeoxyuridine, cladribine, cytarabine, floxuridine, fludarabine, flurouracil (e.g., 5-fluorouracil (5FU)), gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine; and examples of natural source derivatives include docetaxel, etoposide, irinotecan, paclitaxel, teniposide, topotecan, vinblastine, vincristine, vinorelbine, taxol, prednisone, and tamoxifen. Additional examples of chemotherapeutic agents that can be used in the invention include asparaginase and mitotane.
Methods for administration of chemotherapeutic drugs are well known in the art and vary depending on, for example, the particular drug (or combination of drugs) selected, the cancer type and location, and other factors about the patient to be treated (e.g., the age, size, and general health of the patient). Any of the drugs listed above, or
other chemotherapeutic drugs that are known in the art, are administered in conjunction with the mutant Herpes viruses described herein.
The virus and the anticancer agents can be administered, for example, on the same day, e.g., within 0-12 hours (e.g., within 1-8 or 2-6 hours) of one another, or can be administered on separate days, e.g., within 24, 48, or 72 hours, or within a week, of one another, in any order. In addition, they can be administered by the same or different routes, as can be determined to be appropriate by those of skill in this art (see, e.g., above). Specific examples of routes that can be used in the invention include intravenous infusion, the oral route, subcutaneous or intramuscular injection, as well as local administration, by use of catheters or surgery. The appropriate amount of drag to be administered can readily be determined by those of skill in this art and can range, for example, from 1 μg-10 mg kg body weight, e.g., 10 μg-1 mg kg body weight, 25 μg-0.5 mg/kg body weight, or 50 μg-0.25 mg/kg body weight. The drugs can be administered in any appropriate pharmaceutical carrier or diluent, such as physiological saline or in a slow-release formulation.
Examples of cancers can be treated using the methods of the invention, include cancers of nervous-system, for example, astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary tumors (e.g., pituitary adenoma), and medulloblastoma. Other types of cancers that can be treated using the methods of the invention, include, head and neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, lymphoma (Hodgkin's and non-Hodgkin's lymphomas), hepatoma, mesothelioma, epidermoid carcinoma, cancers of the blood (e.g., leukemias), as well as other cancers mentioned herein.
Experimental Results
The invention is based, in part, on the following experimental results, which show the synergistic activities of a mutant Herpes Virus (G207) and two anticancer agents, fluorodeoxyuridine (I) and Mitomycin C (II), in the treatment of cancer. I. Functional Interactions Between Fluorodeoxyuridine-induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus
As is noted above, G207 is an oncolytic herpes simplex virus (HSV), which is attenuated by inactivation of viral ribonucleotide reductase (RR) and deletion of both Yι34.5 genes. The cellular counterparts that can functionally substitute for viral RR and the carboxyl-terminal domain of ICP34.5 are cellular RR and the corresponding homologous domain of the growth arrest and DNA damage protein 34 (GADD34), respectively. Because the thymidylate synthetase (TS) inhibitor fluorodeoxyuridine (FUdR) can alter expression of cellular RR and GADD34, we examined the effect of FUdR on G207 bioactivity with the hypothesis that FUdR-induced cellular changes wUl alter viral proliferation and cytotoxicity. Replication of wild-type HSV-1 was impaired in presence of 10 nM FUdR whereas G207 demonstrated increased replication under the same conditions. Combined use of FUdR and G207 resulted in synergistic cytotoxicity. FUdR exposure caused elevation of RR activity at 10 nM and 100 nM whereas GADD34 was induced only at 100 nM. The effect of enhanced viral replication by FUdR was suppressed by hydroxyurea, a known inhibitor of RR. These results demonstrate that the growth advantage of G207 in FUdR-treated cells is primarily based on an RR-dependent mechanism. Although our findings show that TS inhibition impairs viral replication, the FUdR-induced RR elevation may overcome this disadvantage resulting in enhanced replication of G207. These data provide the cellular basis for the combined use of RR-negative HSV mutants and thymidylate synthetase inhibitors in the treatment of cancer. Our experimental results are described in further detail below.
Materials and Methods Cell lines and culture
HCT8 cells with two different degrees of sensitivity to 5-fluorouracil (5-FU) and FUdR were used for this study. HCT8 cells were obtained from the American Type Culture Collection (CCL-224, Rockville, MD, USA). The resistant cell line was cloned from HCT8 cells after exposure to 15 μM 5-FU for 7 days (HCT8/FU7dR) as previously described (Aschele et al., Cancer Res. 52:1855-1864, 1992). Both cell lines were maintained in RPMI 1640 media supplemented with 10% fetal calf serum (FCS), 100 μg/ml penicillin, and 100 μg/ml streptomycin. Vero cells (African green monkey kidney) were grown in Eagle's minimal essential medium (MEM) supplemented with 10% FCS.
Viruses
Creation of the multi-mutated, replication-competent type-1 herpes virus G207 has been described previously (Mineta et al., Nature Med. 1:983-943, 1995). G207 was constructed from the R3616 mutant based on wild-type HSV-1 strain F. This mutant contains a 1 kb deletion from the coding domains of both γj34.5 loci and an insertion of the Escherichia coli lacZ gene into the ICP6 gene which encodes the large subunit of ribonucleotide reductase. HSV- 1(F) is the parental wild-type virus of G207, whereas KOS is wild-type HSV-1 of different strain. Viruses were propagated on Vero cells. G207 was a gift of S.D. Rabkin and R.L. Martuza. HSV-1 (F) and KOS were provided by MediGene, Inc. (Vancouver, Canada).
p53 mutational analysis
Genomic DNA was extracted from HCT8 and HCT8/7dR cells. Exons 5 through 9 of the p53 gene were amplified by polymerase chain reaction and analyzed for mutations by single-strand confirmation polymorphism.
Cytotoxicity assay
Cytotoxicity of G207 and FUdR (Floxuridine, Roche Laboratories Inc., Nutley,
NJ) was assessed by measuring cytoplasmic lactate dehydrogenase (LDH) activity (CytoTox 96 non-radioactive cytotoxicity assay, Promega, Madison, WI). All cytotoxicity assays were performed in 24-well plates starting with 2 x 104 cells per well.
At various time points following start of treatment, adherent cells were washed with
PBS and cytoplasmic LDH was released by lysis buffer (PBS, 1.2% v/v Triton X-100).
Activity of the lysate was measured with a coupled enzymatic reaction, which converts a tetrazolium salt into a red formazan product. Absorbance was measured at 450 nm using a microplate reader (EL 312e, Bio-Tek Instruments, Winooski, VT). Cytotoxicicty was expressed as percentage of maximal LDH release of treated cells compared to untreated cells (control).
Viral titration
Vero cultures were carried for at least one subculture in E-MEM, 2 mM L- glutamine, 10% FCS. Cultures were plated at a density of 1 x 106 cells per well of 6- well plates and incubated at 37 °C in 5% CO in air in a humidified incubator. The
following day, cultures were washed 2x with PBS, and serial dilutions of cell lysates (0.8 ml/well) were adsorbed onto triplicate dishes for 4 hours at 37°C. Cell lysates were prepared by 4 freeze-thaw cycles. Following adsorption, inoculum was removed, and cultures were overlaid with agar containing medium. Cultures were stained with neutral red 2 days post-inoculation, and plaque formation was assessed the next day.
β-galactosidase activity
Activity of /3-galactosidase was determined by monitoring the conversion of o- nitrophenyl galactoside (ONPG) to o-nitrophenol and galactose (/3-Galactosidase Reporter Assay, Pierce, Rockford, EL). Cells were lysed and incubated with ONPG at 37°C for 30 min. The reaction rate was determined by spectrophotometric measurement of o-nitrophenol at λ=405 nm. Using the molar extinction coefficient for o-nitrophenol (Zχ = 4.5 x 103 M"1 cm"1), one unit of β-galactosidase activity was defined as cleavage of 1 nmol ONPG to o-nitrophenol and galactose in 1 min at 37°C. Histochemical staining for β-galactosidase
Cells were trypsinized, resuspended in media, and washed with PBS. Cytospin slides were prepared by centrifuging 1 ml of a cell suspensions containing 1 x 105 cells at 1000 rpm for 6 min. Slides were stained with X-gal (5-bromo-4-chloro-3-indolyl-β- D-galactopyranoside) and incubated for 4 hours at 37°C. After washing with PBS, slides were counterstained with 0.1% nuclear fast red.
Cell cycle analysis
Cell cycle analysis was performed on nuclear preparations by flow cytometry as previously described (Nϋsse et al., Cytometry 11:813-821, 1990). Briefly, cell monolayers were carefully washed with PBS to remove cellular debris. Following trypsinization, cells were washed in PBS and resuspended in NP40 solution (10 mM NaCI, 3.4 mM sodium citrate, 0.03% NP-40, 63 μM ethidium bromide, 10 μg/ml RNase A). After 1 hour incubation at room temperature, an equal volume of high-sucrose solution (0.25 M sucrose, 78 mM citric acid, 100 μM ethidium bromide) was added. DNA content of ethidium bromide-stained nuclei was determined on FACScalibur. Data were analyzed with FACStation running CellQuest software (Becton Dickinson, San Jose, CA).
Cell extraction of ribonucleotide reductase
Cells grown in 250 cm2-flasks were trypsinized and washed twice in ice-cold PBS. Cells were centrifuged at 300 x g for 5 min at 4°C and resuspended in 3 volumes of Low Salt Extraction Buffer (10 mM HEPES, pH 7.2, 2 mM DTT). Viable cell count of the resuspension was determined by trypan blue exclusion. After 30 min incubation on ice, the cell suspension was drawn lOx through a 28GV2 needle. The crude homogenate was centrifuged at 100,000 x g for 60 min at 4°C to remove cellular debris. The supernatant fraction was dialyzed against 1,000 volumes of the Low Salt Extraction Buffer for 4 hours with one buffer change after 2 hours using dialysis cassettes with a molecular weight cut-off of 10,000 (Slide-A-Lyzer Dialysis Cassettes, Pierce, Rockford, EL). The dialyzed extract was snap-frozen in liquid nitrogen and stored at -80°C until analysis. All extraction procedures were performed at 4°C.
Assay for CDP reductase activity Activity of ribonucleotide reductase was determined by a modified method of
Steeper and Stuart (Steeper et al., Anal. Biochem. 34:123-130, 1970). Conversion of CDP to dCDP was monitored using [14C]CDP (53 mCi/mmol, Movarek Biochemicals, Inc.) as substrate and rattlesnake venom from Crotalus adamanteus (Sigma) to hydrolyze nucleotides to nucleosides. The reaction mixture contained the following concentrations of ingredients in a final volume of 150 μl: 40 μM CDP, 10 μM [14C]CDP (0.08 μCi),
6 mM DTT, 4 mM magnesium acetate, 2 mM ATP, 50 mM HEPES (pH 7.2), and 100 μl extract (0.2-0.7 mg protein). The enzyme reaction was carried out for 30 min at 37°C and stopped by incubation at 100°C for 4 min. Nucleotides were hydrolyzed by adding 50 μl carrier dCMP (6 mM dCMP, 2 mM MgCl2, 6 mM Tris-HCl, pH 8.8) and 25 μl snake venom suspension (50 mg/ml). After 3 hours incubation at 37°C, the reaction mixture was heat-inactivated by boiling for 4 min. Heat-precipitated material was removed by centrifugation at 14,000 x g for 10 min at room temperature. [1 C]deoxycytosine was separated from [14C]cytosine by covalent chromatography using phenylboronic acid-columns (BondElut PBA, Varian, Harbor City, CA). Triethenolamine Buffer (pH 10) was added to the supernatant fraction to a final concentration of 0.4 M and 1 ml of this mixture was applied to the column. Fractions were collected and measured for radioactivity by liquid scintillation spectrometry (LS 6000IC Liquid Scintillation System, Beckman Instruments, Inc., Fullerton, CA). One
unit of enzyme activity was defined as conversion of 1 nmol CDP to the product dCDP in 1 hour at 37°C.
Northern hybridization Total cellular RNA was isolated by guanidine thiocyanate-phenol-chloroform extraction (Chomczynski et al., Anal. Biochem. 162:156-159, 1987). RNA was denatured, electrophoresed through a 1.2% formaldehyde-agarose gel, and blotted to a nitrocellulose membrane by standard techniques. Following prehybridization, membranes were hybridized in 50% formamide at 40°C to a full-length GADD34 and β- actin cDNA probe labeled with [32P]dCTP by the random primer method. Membranes were washed and exposed to Hyperfilm (Amersham pharmacia biotek) at -80°C. Densitometric analysis was carried out on scanned films using the NEH image software. Relative GADD34 levels were calculated as the ratio GADD34/ 3-actin.
Results
Synergistic cytotoxicity ofG207 and FUdR
HCT8 cells were more sensitive to FUdR compared to HCT8/7dR, as demonstrated by lower LDH release and a higher percentage of subGi fraction (Figure 1A, Figures 5A and 5B). Both cell lines showed similar viral cytotoxicity profiles. Viral infection at a multiplicity of infection (MOI) of 1.0 or 0.1 resulted in complete cell kill at day 6 while G207 at an MOI of 0.01 had only marginal cytotoxic effects (Figures IB and 1C). To test the hypothesis that FUdR can enhance viral cytotoxicity, we decided to use G207 at an MOI of 0.01 since viral cytotoxicity at MOI's of 1.0 and 0.1 was excessively high. G207 (MOI 0.01) combined with either 10 nM or 100 nM FUdR resulted in nearly complete kill of HCT8 cells by day 6 (Figure ID). This effect was higher than the calculated additive effect from each single treatment indicating synergistic effects of combined treatment. Furthermore, degree of synergy was more pronounced in HCT8 cells than in the less FUdR-sensitive cell line HCT8/7dR (Figures ID and IE).
Increased β-galactosidase expression in presence ofFudR
To assess the effect of FUdR on viral infectivity, activity of 3-galactosidase was measured as the product of the lacZ reporter gene in G207. Cells infected with G207 at
an MOI of 0.01 followed by treatment with 10 nM FUdR showed the highest total expression of 3-galactosidase at day 3 postinfection (pi), however, when normalized to viable cell count, exposure to 100 nM FUdR resulted in higher β-galactosidase activity than treatment with G207 only (Figures 2A and 2B). Histochemical staining for β- galactosidase of FUdR-exposed cells showed greater staining intensity and a higher proportion of cells positive for staining with X-gal (Figure 2C). The degree of enhanced infection by FUdR was more pronounced for HCT8 than for HCT8/7dR cells.
Replication is enhanced for G207 but decreased for wild-type HSV-1 in the presence of FUdR
Single-step growth analysis demonstrated a 2-log higher viral yield for wild-type HSV (HSV-l(F), KOS) compared to G207 in HCT8 cells. Interestingly, burst size of G207 in the presence of FUdR was 3-fold higher at 36 hours pi than G207 alone, whereas replication of the parental wild-type virus HSV-1 (F) was somewhat inhibited under the same conditions. We tested another wild-type HSV-1 (strain KOS) and found a simUar reduction of replication in presence of 10 nM FUDR (Table 1). Multiple-step growth analysis revealed a significantly higher viral production in the presence of 10 nM FUdR in both cell lines compared to G207 infection alone. Peak titers and overall production of G207 were higher for the parental cell line HCT8 compared to HCT8/7dR cells (Figure 3).
Effect of ydroxyurea on viral replication and β-galactosidase expression
The RR inhibitor hydroxyurea (HU) suppressed viral replication in HCT8 cells by 90%. Furthermore, HU was able to extinguish the FUdR-induced enhanced replication of G207. The degree of inhibition was the same for cells treated with HU alone (1.9 ± 0.5 xl04pfu) and for cells treated with HU and FUdR (2.1 ± 0.5 xl0 pfu). In contrast to viral production, neither FUdR nor HU had significant effects on β- galactosidase expression (Figure 4).
Cell cycle alteration by FUdR
Exposure of asynchronously growing cells to FUdR resulted in an increase of S- phase fraction and a decrease of the GJGo fraction; however, this effect was dependent on drug concentration and cell line. Low FUdR concentrations of 10 nM increased S-
phase fraction by 75% in HCT8 and 37% in HCT8/7dR by 24 hours. By 48 hours both ceU lines showed a majority of cells in S-phase following treatment with 100 nM. In contrast to HCT8 cells, which were completely blocked at 100 nM FUdR at S-phase level, HCT8/7dR cells showed only a transient S-phase increase and were able to transit to an apparent G2/M-phase. Additionally, we observed that 10-20% of HCT8/7dR cells undergo DNA endoreduplication in S-phase in the presence of 100 nM FUdR instead of moving to G2/M. Accumulation of these cells in G2/M may be due to there being 4N G1 cells resulting from this endoreduplication (Figures 5 A and 5B).
Elevated activities of ribonucleotide reductase in the presence of FUdR
Since replication of G207 is dependent on cellular RR, we tested whether the thymidylate synthetase inhibitor FUdR has any effects on this cellular enzyme. Baseline activity of exponentially growing cells was approximately 3.2-fold higher for HCT8 cells compared to the chemoresistant cell line HCT8/7dR. Figure 6 shows the time- dependent course of RR activity during FUdR exposure. FUdR treatment resulted in an increase of RR activity in both cell lines. This increase was transient and peak activities were observed simultaneously with the FUdR-induced S-phase elevation at 24 hours following start of treatment (Figures 5A and 5B). The degree of activity induction was, however, more pronounced in HCT8 compared to HCT8/7dR cells. RR activity in HCT8 treated with 10 nM FUdR remained elevated following peak activity.
Effect of FdUMP on the activity of ribonucleotide reductase
FdUMP is the active metabolite of FUdR and inhibits TS. Activity of mammalian RR is highly regulated by feedback inhibition of deoxynucleotides; we therefore tested the idea that FdUMP, the fluorinated form of dUMP, inhibits the activity of RR, which could interfere with replication of G207. Table 2 shows a dose-dependent decline of enzyme activity. Concentrations of FdUMP at 0.001 to 0.1 mM caused only a moderate inhibition of RR, with approximately 80 to 70% of the activity remaining.
Substantial enzyme inhibition was measured in the presence of 1 mM FdUMP, a 10,000- fold higher concentration than the maximal FUdR concentration used in this study.
Expression of GADD34 in response to FUdR
The GADD34 protein is expressed in response to DNA damage. GADD34 and the viral γi34.5 protein contain similar carboxyl-terminal domains that can functionally sustain protein synthesis under stress conditions. We therefore investigated whether FUdR as a DNA damaging agent can induce expression of GADD34 that can complement the Y234.5 deletions in G207. FUdR at 100 nM induced GADD34 in both cell lines whereas 10 nM had almost no effect. When compared to untreated cells, densitometric reading revealed a 1.9- and 1.6-fold higher mRNA level at 24 and 48 hours, respectively for HCT8 and a 1.9-fold higher level at 48 hours for HCT8/7dR cells (Figure 7).
Table 1: Replication of wild-type HSV-1 and G207 in presence and absence of FUdR
Viral yield [105 x : pfuf
HSV-1 (F) KOS G207
Virus alone 325 ± 25 119 + 10 1.16 ± 0.22
Virus + 10 nM FUdR 215 + 10 57 + 2 3.42 + 0.28
Fold increase 0.66 0.48 2.95 a HCT8 cells were infected with HSV- 1(F), KOS and G207 at an MOI of 2. After adsorption for 1 hour at 37°C, inoculum was removed, cells were washed with PBS, and medium containing 10 nM FUdR or control medium without FUdR was added. At 36 hours pi cells and supernatant were harvested and lysates were titrated on Vero cells by standard plaque assay. Data are presented as avg ± SEM of tliree independent determinations.
Table 2: Effect of FdUMP on ribonucleotide reductase activity
FdUMP RR activity a,b Activity Inhibition
[mM] [nmol dCDP / h] [%] [%]
0 0.61 ± 0.05 100 0
0.001 0.47 ± 0.02 77.0 23.0
0.01 0.45 ± 0.02 73.8 26.2
0.1 0.43 ± 0.03 70.5 29.5
1 0.24 ± 0.02 39.3 60.7
10 0.14 + 0.01 22.9 77.1
a Ribonucleotide reductase was extracted from exponentially growing HCT8 cells as described under "Experimental Procedure". Extracts were incubated with FdUMP in cumulative concentrations and ribonucleotide reductase activity was measured. Data are presented as avg ± SEM of three independent determinations of ribonucleotide reductase activity. b 100 μl dialyzed cell extract contained 0.65 mg protein.
II. Synergistic Anticancer Activity of Mitomycin C and a Y34.5 Deleted Oncolytic Herpes Virus (G207) is Mediated by Upregulation of GADD34
Oncolytic viruses used for gene therapy have been genetically modified to selectively target tumor cells while sparing normal host tissue. As is described above, the multimutant virus G207 has been attenuated by inactivation of viral ribonucleotide reductase and by deletion of both viral γ34.5 genes. Although G207 has effectively killed many tomor types in experimental models, it is well established that γ34.5 mutants exhibit markedly reduced antitumor efficacy when compared to viruses maintaining this gene. The mammalian homologue to the γ34.5 gene product is the GADD34 protein. This protein can functionally substitute for the γ34.5 gene and is also upregulated during DNA damage. The chemotherapy agent Mitomycin C was used in combination with G207 to upregulate GADD34 and to complement the γ34.5 gene deletion in an attempt to increase viral toxicity and antitumor efficacy. Using both the isobologram method and combination-index method of Chou-Talaley, significant synergism was demonstrated between Mitomycin C and G207 as treatment for gastric cancer both in
vitro and in vivo. As a result of such synergism, a dose-reduction for each agent can be accomplished over a wide range of drug-effect levels without sacrificing tomor cell kill. As determined by Northern blot analysis, expression of GADD34 mRNA was increased by Mitomycin C treatment. These data indicate that Mitomycin C can be used to selectively restore the virulent phenotype of the γ34.5 gene in G207, and also provide a ceUular basis for the combined use of DNA damaging agents and γ34.5 HSV mutants in the treatment of cancer. Our experimental results are described in further detail below.
Materials and Methods Cell culture
The human gastric cancer cell line OCUM-2MD3 was obtained as a generous gift from Dr. Masakazu Yashiro at Osaka City University Medical School, Japan, and was maintained in DMEM HG supplemented with 2mM L-glutamine, 0.5 mM NaPyruvate, 10% fetal calf serum (FCS), 1% penicillin and 1% streptomycin. The human gastric cancer cell line MKN-45-P was obtained as a generous gift from Dr. Yutaka Yoneumura at Kanazawa University, Japan, and was maintained in RPMI supplemented with 10% FCS, 1% penicillin, and 1% streptomycin. The human lung cancer cell line A549 was obtained from the ATCC and maintained in F-12 supplemented with 10% FCS, 1% penicillin, and 1% streptomycin. Cells were all maintained in a 5% CO2 humidified incubator.
Virus
G207 is multi-mutated, replication-competent HSV constructed with deletions of bothγi34.5 neurovirulence genes, and an E.coli lacZ insertion atUL.39, which codes for the large subunit of ribonucleotide reductase. The construction of G207 has been described elsewhere.
Animals
Athymic nude mice 4-6 weeks old were used for all animal experiments. Animal stadies were approved by the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee and performed under strict guidelines. Procedures were performed using methoxyflurane inhalation for anesthesia.
Generation ofperitoneally disseminated gastric cancer
An established murine xenograft model of gastric carcinomatosis was used as previously described (Bennett et al., Journal of Molecular Medicine 78:166-174, 2000; Yashiro et al., Clin. Exp. Metastasis 14:43-54, 1996). Intraperitoneal (i.p.) injection of 2xl06 OCUM-2MD3 cells reliably develops disseminated peritoneal tumor that seeds the omentam, small and large bowel mesentery, diaphragm, gonadal fat and hepatic hilum. Macroscopic nodules are present within three days after injection, and the development of overwhelming tomor burden, bloody ascites and cachexia occurs by four weeks post-injection. To assess tumor burden, animals were eviscerated at sacrifice and peritoneal tumor was stripped from associated abdominal organs as previously described . Tumor burden was then assessed by weight.
In vitro cytotoxicity of MMC and G207
Cytotoxicity assays were performed by plating lxlO4 cells/well into 96 well assay plates (Costar, Corning Inc., Corning, NY). MKΝ-45-P and OCUM-2MD3 cells were treated with either media alone (control wells), Mitomycin C alone (Bristol
Laboratories, Princeton, NJ), G207 alone, or combination therapy using both G207 and MMC. Combination therapy was performed using serial dilutions of MMC and G207 in a 1:10 ratio for the OCUM-2MD3 cell line, and a 1:25 ratio for the MKN-45-P cell line. These ratios were determined by estimating the ED50 for each drug in initial experiments and by using these doses to determine the ratio of combination therapy. Percent cell survival for each group (vs. controls) was calculated 5d after treatment using a standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide) bioassay. A micro-plate reader was used to evaluate for the presence of the MTT-formazan product at 550 nm. Background optical density (OD) was subtracted from the OD readings of all samples. Cell viability was then calculated by dividing the mean absorbance (OD)(n=6) of the treated wells by the mean absorbance (OD)(n=6) of the untreated (control) wells.
Pharmacologic analysis of synergy between MMC and G207
The multiple drug effect analysis of Chou and Talalay was used to determine the pharmacologic interaction between G207 and MMC. This method defines the expected additive effect of two agents and then quantifies synergism or antagonism by
determining how much the combination effect differs from the expected additive effect. The equations and computer software used for data analysis have been described in detail elsewhere (Chou, T., editors. Academic Press, New York. 61-102, 1991; Chou et al., Advances in Enzyme Regulation 22:27-55, 1984; Chou et al., Manual and Software for IBM-PC 1987; Chou, J., Academic Press, New York 223-244, 1991). The combination index equation is used to precisely analyze two-drug combinations. Interpretation of CI values are defined such that a CI=1 indicates an additive effect, while a CI<1 and a CI>1 indicate synergism and antagonism, respectively. Cytotoxicity data obtained from the experiments described above were used in the Chou-Talalay analysis. These data generated CI values for each dose and corresponding effect level, referred to as the fraction affected (Fa). Based on the actual experimental data, computer software was used to calculate serial CI values over an entire range of effect levels (Fa) from 5-95%. These data were then used to generate Fa-CI plots, which is an effect-oriented means of presenting the data. Data were also analyzed by the isobologram technique, which is dose-oriented. The axes on an isobologram represent the doses of each drag. For any given Fa value, two points on the x and y axes are chosen that correspond to the doses of each drug necessary to generate that given Fa value. The straight line drawn between these two points corresponds to the possible combination doses that would be required to generate the same Fa value, assuming that the interaction between the two drags is strictly additive. The observed experimental concentrations actually required to achieve a given Fa value are then added to the plot. If these points lie on the straight line then the effect is additive at that Fa value. If the point lies to the left of the straight line then the effect is synergistic, and if the point lies to the right of the straight line then the effect is antagonistic at that Fa value. Another calculation available using the combination index method is the dose-reduction index (DRI). The DRI is a determination of the fold-dose reduction allowed for each drug when given in synergistic combination, as compared to the concentration of single agent therapy needed to achieve the same effect level. A DRI>1 signifies a favorable reduction in toxicity while still maintaining therapeutic efficacy.
In vitro viral growth analysis
The abUity of G207 to replicate within OCUM-2MD3cells in the presence of MMC was evaluated by viral growth analysis. 1.5xl05 OCUM-2MD3 cells/well were plated into 6-well plates (Costar, Corning Inc., Corning, NY). Cells were then infected
with either G207 at an MOI=0.01 alone, or with G207 at an MOI=0.01 in combination with MMC at 0.01 μg/cc, 0.02 μg/cc, or 0.04 μg/cc. Cells and media were harvested at Oh, 24h, 48h, 72h, and 120h post-infection. After three cycles of freeze-thaw lysis, standard plaque assay was performed on Vero cells to evaluate viral titers. All samples were performed in triplicate.
Northern Hybridization Analysis for GADD34 in cells treated with MMC in vitro
Cells were cultured with 12cc culture media containing 0 μg/ml (untreated), 0.005 μg/ml (low dose), or 0.04 μg/ml (high dose) of Mitomycin-C (Bristol Laboratories, Princeton, NJ). Cells were harvested by trypsinization at 24 and 48 hours. Total RNA was prepared using a total RNA isolation system (Promega, Madison, WI) and RNA content was measured by optical density at 260 nm. 7 μg of RNA per sample was loaded in a denaturing 1.2% agarose gel. Electrophoretic separation, RNA transfer to a nitrocellulose membrane (Intergen, Purchase, NY), hybridization (50% formamide at 40°C), and autoradiographic identification were done by standard techniques. The cDNA clone GADD34 containing a 2.4 kb insert was provided by Dr.A. Fornace, Jr, and the cDNA clone α-actin containing a 1.1 kb insert was acquired from ATCC (Manassas, VAXHollander et al., J. Biol. Chem. 272:13731-13737, 1997). cDNA that had been excised from plasmid vectors was labelled with [32P]dCTP by the random-primer labelling method (Stratagene, La Jolla, CA).
Treatment of gastric carcinomatosis with intraperitoneal G207 and MMC
The ability of G207 and MMC to reduce tomor burden in vivo was evaluated in a model of gastric carcinomatosis. Animals were all injected i.p. with 2xl06 OCUM- 2MD3 cells and treated 3d later. Experimental groups (n=7) were treated by intraperitoneal injection of serum free media (controls), lxlO6 pfu of G207, 5xl06 pfu of G207, 0.1 mg/kg MMC, or as combination therapy using 0.1 mg/kg MMC with either lxlO6 or 5xl06 pfu of G207. Animals were sacrificed 4 weeks later and tumor burden was assessed as described (Bennett et al., Journal of Molecular Medicine 78:166-174, 2000).
Results
In vitro cytotoxicity of MMC and G207
Both G207 and MMC demonstrate dose-dependent cytotoxicity against OCUM- 2MD3 and MKN-45-P gastric cancer cells. Combination therapy killed more tomor cells than either single agent alone and showed greater efficacy than the expected additive effect. Data are presented as mean (±SEM) cell survival vs. controls for OCUM-2MD3 cells (Figure 8A) and for MKN-45-P cells (Figure 8B).
Pharmacologic analysis of synergy between MMC and G207 Two methods were employed to determine synergy between G207 and MMC, the combination-index method and the isobologram method. Chou-Talaley analysis demonstrated that the CI values remained <1 over the entire range of Fa values for both the OCUM-2MD3 (Figure 9A) and MKN-45-P (Figure 9B) cell lines. Moderate synergism was demonstrated for the OCUM-2MD3 cell line, while strong synergism was demonstrated for the MKN-45-P cell line. The dose-reduction index (DRI) was calculated for each Fa value. For the OCUM-2MD3 cell line, both MMC and G207 doses could be lowered 2-3 fold when given as combination therapy (Table 3). For the MKN-45-P cell line, MMC doses could be lowered 2-9 fold and G207 doses could be lowered 2-4 fold when given as combination therapy (Table 4). DRI values >1 indicate that a reduction in toxicity can be achieved without loss of efficacy. Isobolograms were constructed for the doses of MMC and G207 necessary to kill 90% of cells (ED90), 70% of cells (ED70) and 50% of cells (ED50) (Figures 10A and 10B). Experimental combination data points were at drug and viral concentrations well below the expected additive effect line for each of these Fa values (0.5, 0.7, and 0.9). These studies both confirmed synergism between MMC and G207 for both cell lines.
In vitro viral growth analysis
Replication of G207 in OCUM-2MD3 cells demonstrated a decline in viral yield in the presence of higher doses of MMC. A 155-fold increase in viral titers was observed 5d after infecting OCUM-2MD3 cells with G207. In the presence of 0.01 μg/cc MMC, a 24-fold increase in viral titers was observed over 5d post-infection. In the presence of 0.02 and 0.04 μg/cc MMC, there was an 8-fold and 2-fold increase in viral yields, respectively. Lower viral yields measured with combination chemotherapy
may be secondary to significant loss of cellular substrate, especially given the synergistic cytotoxicity of combination therapy.
Northern Hybridization Analysis for GADD34 in cells treated with MMC in vitro RNA extracted from cells that were not treated with MMC served as negative controls (lane 1), while positive controls (lane 6) demonstrated the expected GADD34 band at 2.4 kb (Figure 11). In all conditions, an approximately equal amount of the cellular α-actin gene was expressed. OCUM cells harvested 24 hours (lane 2) after treatment with low dose Mitomycin C (0.005 μg/cc) did not show any band at the expected size, while cells treated with high dose MMC (0.04 μg/cc) demonstrated a significant 2.4 kb band (lane 3). At 24 hours after high dose treatment a 2.49 fold increase in the intensity of the GADD34 band was measured when compared to the negative control. OCUM ceUs harvested 48 hours after treatment with low dose MMC did not show any GADD34 band (lane 4), while high dose therapy showed a discrete ( band at 2.4 kb (lane 5)(Figure 11). At 48 hours after high dose treatment, a 3.21 fold • increase in intensity was noted (Figure 11).
Treatment of gastric carcinomatosis with intraperitoneal G207 and MMC
Mice with gastric carcinomatosis were treated intraperitoneally with G207, MMC, or a combination of these agents. Efficacy of therapy was evaluated by weighing peritoneal tumor burden from mice at the time of sacrifice. Mean peritoneal tomor burden (±SEM) was 2470 (±330) mg for control mice, 1210 (±300) mg for mice treated with lxlO6 pfu of G207 (P=0.02 vs. controls), and 1490 (±310) mg for mice treated with 0.1 mg/kg MMC (P=0.06 vs. controls) (Figure 12). Combination therapy using lxlO6 pfu of G207 and 0.1 mg/kg MMC resulted in a mean tomor burden of 350 (±150) mg (P<0.001 vs. controls), which was statistically different from lxlO6 pfu of G207 alone (P=0.03) and from MMC therapy alone (P=0.01)(Figure 5). Viral therapy with 5xl06 pfu of G207 resulted in a mean tumor burden of 990 (±320) mg (P<0.01 vs. controls)(data not shown). Combination therapy using 5xl06 pfu of G207 and 0.1 mg/kg MMC resulted in a mean tomor burden of 100 (±60) mg (P<0.01 vs. controls), which was statistically different from 5xl06 pfu of G207 alone (P=0.04) and from MMC therapy alone (P<0.01).
Table 3: Drug and viral doses needed to kill various fractions (Fa) of OCUM-2MD3 cells, and fold-dose reduction possible when agents are delivered in combination.
Fraction MMC alone G207 alone MMC dose G207 dose affected (Fa) (ug/cc) (MOI) reduction index reduction index
10% 0.009 0.08 3.6 3.0
20% 0.014 0.11 3.5 2.8
30% 0.017 0.14 3.4 2.7
40% 0.021 0.17 3.3 2.6
50% 0.026 0.20 3.3 2.6
60% 0.031 0.24 3.2 2.5
70% 0.038 0.29 3.2 2.5
80% 0.048 0.37 3.1 2.4
90% 0.070 0.53 3.0 2.3
95% 0.100 0.74 2.9 2.2
Table 4: Drug and viral doses needed to kill various fractions (Fa) of MKN-45-P cells, and fold-dose reduction possible when agents are delivered in combination.
Fraction MMC alone G207 alone MMC dose G207 dose affected (Fa) (ug/cc) (MOI) reduction index reduction index
10% 0.014 0.34 2.4 2.3
20% 0.027 0.57 3.0 2.6
30% 0.040 0.79 3.5 2.7
40% 0.056 1.05 3.9 2.9
50% 0.077 1.35 4.3 3.0
60% 0.105 1.73 '• 4.8 3.2
70% 0.147 2.28 5.4 3.3
80% 0.222 3.19 6.2 3.5
90% 0.413 5.28 7.6 3.9
95% 0.732 8.41 9.2 4.2
All references cited above are incorporated by reference in their entirety. Other embodiments are within the following claims.
What is claimed is:
Claims (29)
1. A method of treating cancer in a patient, said method comprising administering to said patient (i) an attenuated herpes virus in which a γ34.5 gene is inactivated, and (ii) a chemotherapeutic drag.
2. The method of claim 1, wherein a ribonucleotide reductase gene is inactivated in said attenuated herpes virus.
3. The method of claim 1, wherein two γ34.5 genes are inactivated in said attenuated herpes virus.
4. The method of claim 1, wherein said attenuated herpes virus is G207.
5. The method of claim 1, wherein said chemotherapeutic drug is an alkylating agent.
6. The method of claim 5, wherein said alkylating agent is selected from the group consisting of busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, and thiotepa.
7. The method of claim 1, wherein said chemotherapeutic drug is an antineoplastic antibiotic.
8. The method of claim 7, wherein said antineoplastic antibiotic is selected from the group consisting of bleomycin, dactinomycin, daunorabicin, doxorubicin, idarubicin, mitomycin, mitoxantrone, pentostatin, and plicamycin.
9. The method of claim 8, wherein antineoplastic antibiotic is mitomycin C.
10. The method of claim 1, wherein said chemotherapeutic drug is an antimetabolite.
11. The method of claim 10, wherein said antimetabolite is selected from the group consisting of thymidylate synthetase inhibitors, cladribine, cytarabine, floxuridine, fludarabine, flurouracU, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine.
12. The method of claim 11, wherein said thymidylate synthetase inhibitor is fluorodeoxyuridine.
13. The method of claim 1, wherein said cancer is selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary adenoma, meduUoblastoma, head arid neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hepatoma, mesothelioma, epidermoid carcinoma, and cancers of the blood.
14. The method of claim 1, wherein said herpes virus comprises a gene encoding a heterologous gene product.
15. The method of claim 14, wherein said heterologous gene product comprises a vaccine antigen.
16. The method of claim 14, wherein said heterologous gene product comprises an immunomodulatory protein.
17. A method of treating cancer in a patient, said method comprising administering to said patient (i) an attenuated herpes virus in which a ribonucleotide reductase gene is inactivated and (ii) a chemotherapeutic drug.
18. The method of claim 17, wherein said chemotherapeutic drug is an alkylating agent.
19. The method of claim 18, wherein said alkylating agent is selected from the group consisting of busulfan, caroplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mecholarethamine, melphalan, procarbazine, streptozocin, and thiotepa.
20. The method of claim 17, wherein said chemotherapeutic drug is an antineoplastic antibiotic.
21. The method of claim 20, wherein said antineoplastic antibiotic is selected from the group consisting of bleomycin, dactinomycin, daunorabicin, doxorubicin, idarubicin, mitomycin, mitoxantrone, pentostatin, and plicamycin.
22. The method of claim 21, wherein antineoplastic antibiotic is mitomycin C.
23. The method of claim 17, wherein said chemotherapeutic drug is an antimetabolite.
24. The method of claim 23, wherein said antimetabolite is selected from the group consisting of thymidylate synthetase inhibitors, cladribine, cytarabine, floxuridine, fludarabine, flurouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine.
25. The method of claim 24, wherein said thymidylate synthetase inhibitor is fluorodeoxyuridine.
26. The method of claim 17, wherein said cancer is selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary adenoma, meduUoblastoma, head and neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tomor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hepatoma, mesothelioma, epidermoid carcinoma, and cancers of the blood.
27. The method of claim 17, wherein said herpes virus comprises a gene encoding a heterologous gene product.
28. The method of claim 27, wherein said heterologous gene product comprises a vaccine antigen.
29. The method of claim 27, wherein said heterologous gene product comprises an immunomodulatory protein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20854600P | 2000-06-01 | 2000-06-01 | |
US60/208,546 | 2000-06-01 | ||
PCT/US2001/017894 WO2001091789A2 (en) | 2000-06-01 | 2001-06-01 | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001268146A1 true AU2001268146A1 (en) | 2002-02-28 |
AU2001268146B2 AU2001268146B2 (en) | 2005-09-22 |
Family
ID=22774981
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6814601A Pending AU6814601A (en) | 2000-06-01 | 2001-06-01 | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
AU2001268146A Ceased AU2001268146B2 (en) | 2000-06-01 | 2001-06-01 | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6814601A Pending AU6814601A (en) | 2000-06-01 | 2001-06-01 | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
Country Status (6)
Country | Link |
---|---|
US (2) | US20020071832A1 (en) |
EP (1) | EP1286678A2 (en) |
JP (1) | JP2004515461A (en) |
AU (2) | AU6814601A (en) |
CA (1) | CA2409932A1 (en) |
WO (1) | WO2001091789A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4212897B2 (en) | 2001-03-27 | 2009-01-21 | 具紀 藤堂 | Viruses and their use in therapy |
US20050255085A1 (en) * | 2002-03-01 | 2005-11-17 | Yuman Fong | Prevention of recurrence and metastasis of cancer |
JP2004099584A (en) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Antitumor agent using hsv |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20050043215A1 (en) | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
US8529625B2 (en) | 2003-08-22 | 2013-09-10 | Smith & Nephew, Inc. | Tissue repair and replacement |
CN1946421B (en) * | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | Cancer treatment using viruses and camptothecins |
US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
RU2435586C2 (en) * | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Cancer treatment with application of viruses fluoropyrimidines and camptothecins |
US20090317456A1 (en) * | 2006-10-13 | 2009-12-24 | Medigene Ag | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
EP2171071B1 (en) | 2007-06-15 | 2015-08-05 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6139834A (en) * | 1994-06-23 | 2000-10-31 | Georgetown University | Replication-competent Herpes simplex virus mediates destruction of neplastic cells |
US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
US6509020B1 (en) * | 1997-03-27 | 2003-01-21 | The University Of Cincinnati | Replication-competent herpes simplex virus |
EP1073442A1 (en) * | 1998-04-30 | 2001-02-07 | The General Hospital Corporation | Combination viral-based and gene-based therapy of tumors |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
-
2001
- 2001-06-01 EP EP01946051A patent/EP1286678A2/en not_active Withdrawn
- 2001-06-01 CA CA002409932A patent/CA2409932A1/en not_active Abandoned
- 2001-06-01 US US09/872,468 patent/US20020071832A1/en not_active Abandoned
- 2001-06-01 WO PCT/US2001/017894 patent/WO2001091789A2/en active IP Right Grant
- 2001-06-01 JP JP2001587802A patent/JP2004515461A/en active Pending
- 2001-06-01 AU AU6814601A patent/AU6814601A/en active Pending
- 2001-06-01 AU AU2001268146A patent/AU2001268146B2/en not_active Ceased
-
2003
- 2003-02-03 US US10/358,096 patent/US20030228281A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ning et al. | Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy | |
Bennett et al. | Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134. 5 deleted oncolytic herpes virus (G207) | |
JP5674210B2 (en) | Use of a combination of myxoma virus and rapamycin for therapeutic treatment | |
Nakamura et al. | Regulation of herpes simplex virus γ 1 34.5 expression and oncolysis of diffuse liver metastases by Myb34. 5 | |
JPH10501990A (en) | Replicating herpes simplex virus mediates neoplastic cell destruction | |
US7514252B2 (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression | |
Cinatl Jr et al. | Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma | |
AU2001268146B2 (en) | Use of mutant herpes viruses and anticancer agents in the treatment of cancer | |
Eisenberg et al. | 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer | |
Stanziale et al. | Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase | |
US20220096578A1 (en) | Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virus | |
AU2001268146A1 (en) | Use of mutant herpes viruses and anticancer agents in the treatment of cancer | |
Kim et al. | Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck | |
WO2018058258A1 (en) | Recombinant oncolytic viruses for cancer therapy | |
CN110982794A (en) | Modified herpes simplex virus | |
CN110982795B (en) | Herpes simplex virus and application thereof | |
CN112243378A (en) | Recombinant herpes simplex virus for cancer immunotherapy | |
Wildner et al. | Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan | |
JP2003508055A (en) | Cell-specific and / or tumor-specific promoter retargeting of herpes γ34.5 gene expression | |
WO2020106566A1 (en) | Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
EP1486212A1 (en) | Combination of a mutant herepes virus and irinotecan for the treatment of cancer | |
Kelly et al. | Attenuated multimutated herpes simplex virus‐1 effectively treats prostate carcinomas with neural invasion while preserving nerve function | |
JP2004529158A (en) | Mixed tumoricidal herpesvirus vector | |
Todo et al. | Oncolytic herpes simplex virus (G207) therapy: from basic to clinical | |
Aghi et al. | Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair |